Coherus Biosciences | CHRS - Gross Profit On Sales


Coherus Biosciences reported $8.7M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
ALKERMES USD 375.31M 43.98M Jun/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amarin USD 23.17M 961K Dec/2025
Amgen USD 5.87B 1.02B Mar/2026
Baxter International USD 1.14B 251M Jun/2026
Biogen USD 2.12B 307M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Coherus Biosciences USD 8.7M 853K Dec/2025
Eli Lilly USD 16.22B 301.7M Mar/2026
Fujifilm JPY 376.67B 29.16B Mar/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Merck USD 12.09B 1.24B Mar/2026
Myriad Genetics USD 146.8M 3M Dec/2025
Pacira USD 133.91M 7.27M Jun/2026
Perrigo USD 313.9M 11.6M Jun/2026
Pfizer USD -248M 11.29B Jun/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Teva Pharmaceutical Industries USD 2.15B 45M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026
Xencor USD 51.22M 46.7M Jun/2026
Zoetis USD 1.76B 140M Jun/2026